Summary
An amended patent must not present the skilled person with technical information which is not directly and unambiguously disclosed, expressly or implicitly, by the application as filed. A feature taken from an embodiment may be omitted only where the skilled person would recognise that it is non-essential, not indispensable to the invention’s function, and removable without compensating modification.
Obviousness requires the structured assessment to be undertaken without hindsight. An invention may lie in achieving known functionality by a technically useful and less resource-intensive arrangement. Patent claims are construed in their full specification context, not by isolating words or confining them to preferred embodiments.
Factual background
Nokia OYJ (Nokia Corporation) v IPCom GmbH & Co Kg concerned a European patent for controlling mobile-phone access to a shared random access channel in a UMTS network. The claimed system allowed mobiles in authorised user classes to gain access independently of a lottery, while other mobiles could obtain access by succeeding in the lottery.
Floyd J held the patent partially valid after amendment, found that Nokia’s A2 device infringed, and found that certain other devices did not infringe: [2011] EWHC 1470 (Pat). Nokia appealed the findings on added matter, obviousness over common general knowledge, GSM/GPRS and Farsta, insufficiency, and infringement by the A2.
The central issues were whether the amended claim was directly and unambiguously disclosed by the original application, whether the two routes of access were obvious, and whether the A2’s delayed-access calculation met the claim.
Held
Appeal dismissed. Kitchin LJ, with whom Etherton and Laws LJJ agreed, upheld the judge’s conclusions on validity and infringement.
The court applied EPC, article 123(2). The decisive question was whether the amendment conveyed new information about the invention which the skilled person could not derive directly and unambiguously from the application. The original application disclosed the 13-bit embodiment as capable of operating independently of the 10-bit embodiment. It also disclosed the essential two routes of access: class-based access independent of the threshold evaluation, and lottery-based access for other mobiles.
The omitted service bits and the omitted enquiry whether a mobile belonged to a class did not add matter. The application showed that information components could be omitted. The omitted features were neither explained as essential nor indispensable to the claimed two-route functionality, and their removal required no compensating alteration. Nor did the claim prescribe a particular order of processing.
The patent was not obvious. The known GSM/GPRS system used class barring followed by a lottery. The claimed arrangement instead provided dynamic horizontal control of privileged groups and vertical control of other users through the threshold. IS-95 provided broadly similar functionality but with greater signalling complexity. The court accepted that achieving the same functionality in a different, less bandwidth-intensive way could involve an inventive step. It also rejected a hindsight-based attack built from common general knowledge and held that Farsta taught class barring in extreme overload, not a lottery bypass.
On construction, the claim required that some classes be permitted to access the channel independently of the lottery. It did not encompass GSM/GPRS class barring. The reference to a UMTS network meant the draft UMTS standard at the filing date; a workable system could then be built, so the claim was sufficient.
The A2 infringed. Its formula made an indirect comparison between the random number and threshold. The result determined whether access was immediate or delayed, which was a determination of access permission within the natural meaning of the claim.
The court’s approach to earlier authorities
Available to signed-in members.
Appellate history
- Court of Appeal (Civil Division) Dismissed Nokia’s appeal and affirmed the judgment below: [2012] EWCA Civ 567 .
- High Court of Justice, Chancery Division, Patents Court Floyd J held the patent partially valid following amendment, found infringement by the A2 device, and rejected infringement by certain other devices: [2011] EWHC 1470 (Pat) .
Appeal route
- Appealed from[2011] EWHC 1470 (Pat)This appealappeal dismissed
- This judgment [2012] EWCA Civ 567 Court of Appeal (Civil Division)
Key cases cited
18 authorities cited.
- Conor Medsystems Incorporated (Respondents) v Angiotech Pharmaceuticals Incorporated and others (Appellants) [2008] UKHL 49
- Kirin-Amgen Inc v Hoechst Marion Roussel Ltd [2005] RPC 9
- Biogen Inc. v Medeva Plc [1997] RPC 1
- Actavis UK Ltd v Novartis AG [2010] EWCA Civ 82
- Napp Pharmaceutical Holdings Ltd v Ratiopharm GmbH [2009] EWCA Civ 252
- Vector Corporation v Glatt Air Techniques Inc [2007] EWCA Civ 805
- Pozzoli Spa v BDMO SA & Anor [2007] EWCA Civ 588
- Ratiopharm GMBH v NAPP Pharmaceutical Holdings Ltd [2008] EWHC 3070 (Pat)
- Abbott Laboratories v Evysio [2008] RPC 23
- Generics (UK) Ltd v H Lundbeck A/S [2007] RPC 32
- Palmaz’s European Patents [1999] RPC 47
- AC Edwards v Acme Signs & Displays [1992] RPC 131
- Bonzel v Intervention [1991] RPC 553
- T 0260/85 Coaxial connector/AMP OJ EPO 1989, 105
- Case G 2/10
- T 0025/03 T 0025/03
- T 0284/94 T 0284/94
- T 0331/87 Houdaille T 0331/87
Sign in to see how the court treated each authority. A free account is enough.
Cases citing this case
35 later cases · 28 positive · 6 neutral · 1 caution
Most senior citing decisions:
- Ipcom GmbH & Co KG v HTC Europe Co Ltd & Ors [2017] EWCA Civ 90 applied
- Novartis Ag & Ors v Focus Pharmaceuticals UK Ltd & Ors [2016] EWCA Civ 1295 applied
- Idenix Pharmaceuticals Inc v Gilead Sciences Inc & Ors [2016] EWCA Civ 1089 applied
- (1) Teva UK Ltd (2) Teva Pharmaceutical Industries Ltd v Leo Pharma A/s [2015] EWCA Civ 779
- Virgin Atlantic Airways Ltd v Jet Airways (India) Ltd & Ors [2013] EWCA Civ 1713
- Sudarshan Chemical Industries Ltd v Clariant Produkte (Deutschland) GmbH [2013] EWCA Civ 919
- BioNTech SE & Anor v CureVac SE & Anor [2024] EWHC 2538 (Pat)
- Modernatx Inc v Pfizer Limited & Ors [2024] EWHC 1695 (Pat)
- Abbott Diabetes Care Inc & Ors v Dexcom Inc & Ors [2024] EWHC 1664 (Pat)
- Abbott Diabetes Care Incorporated & Ors v Dexcom Incorporated & Ors [2023] EWHC 2591 (Ch)
Sign in for the full treatment table, including the other 25 cases. A free account is enough.